Clinical Trials Browser

Phase 3 × Completed × enzalutamide × Clear all

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Phase 3 Completed

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

Phase 3 Completed

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT04934722 2025-10-01

KEYNOTE-991

Phase 3 Completed

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02975934 2025-07-25

TRITON3

Phase 3 Completed

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

Phase 3 Completed

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03016312 2024-08-09

IMbassador250

Phase 3 Completed

759 enrolled 22 charts

Prostatic Neoplasms, Castration-Resistant

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 3 FDA

Metastatic Castration-resistant Prostate Cancer

NCT01212991 2020-03-17

PREVAIL

Phase 3 Completed

1,717 enrolled 20 charts

Prostatic Neoplasms

NCT00974311 2018-12-11

AFFIRM

Phase 3 Completed

1,199 enrolled 24 charts

Prostatic Neoplasms